(±)-Terpinen-4-ol
Cat.No:IT0950 Solarbio
CAS:562-74-3
Molecular Formula:C10H18O
Molecular Weight:154.25
Storage:Store at 2-8℃,2 years
Purity:GC≥95%
Appearance:Colorless to light yellow Liquid
Qty:
Size:
{{cart_num}}
My Cart>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Others >
(±)-Terpinen-4-olCAS:562-74-3
Molecular Formula:C10H18O
Molecular Weight:154.25
Storage:Store at 2-8℃,2 years
Purity:GC≥95%
Appearance:Colorless to light yellow Liquid
Qty:
Size:
CAS | 562-74-3 |
Name | (±)-Terpinen-4-ol |
Molecular Formula | C10H18O |
Molecular Weight | 154.25 |
Solubility | Soluble in Water/DMSO |
Purity | GC≥95% |
Appearance | Colorless to light yellow Liquid |
Storage | Store at 2-8℃,2 years |
Density | 0.933g/mL |
EC | EINECS 209-235-5 |
MDL | MFCD00001562 |
SMILES | OC1(C(C)C)CC=C(C)CC1 |
InChIKey | WRYLYDPHFGVWKC-UHFFFAOYSA-N |
InChI | InChI=1S/C10H18O/c1-8(2)10(11)6-4-9(3)5-7-10/h4,8,11H,5-7H2,1-3H3 |
PubChem CID | 11230 |
Target Point | Others |
Passage | Others |
Background | Terpinen-4-ol is the main bioactive component of tea tree oil. |
Data Literature Source | [1]. Hart PH,et al. Terpinen-4-ol,the main component of the essential oil of Melaleuca alternifolia (tea tree oil),suppresses inflammatory mediator production by activated human monocytes. Inflamm Res. 2000 Nov;49(11):619-26. [2]. Shapira S,et al. Terpinen-4-ol: A Novel and Promising Therapeutic Agent for Human Gastrointestinal Cancers. PLoS One. 2016 Jun 8;11(6):e0156540. |
Unit | Bottle |
Specification | 0.5mL |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.